Released May 9, 2018, after the close
10-Q filed May 11, 2018, 41 days after period end · 0001493152-18-006666
Q1 2018 · 10-Q
Revenue$5.76M$5.76M +10.1% vs Q1 2017+8.8% vs Q4 2017
Net Income-$409.00K-$409.00K N/M vs Q1 2017N/M vs Q4 2017
EPS Diluted-$0.16-$0.16 N/M vs Q1 2017no prior Q4 2017 on file
Operating Income-$313,000N/M
Operating Cash Flow-$120,000N/M
Free Cash Flowderived-$289,000N/M
Margins · derived
Operating margin-5.4%+10.5 pt vs Q1 2017
Net margin-7.1%−5.4 pt vs Q1 2017
What the release said
The release
Same quarter
| Metric | Q1 2018 | Q1 2017 | Q1 2016 | Q1 2015 |
|---|---|---|---|---|
| Revenue | $5.76M | $5.23M | $5.48M | $5.73M |
| Net Income | -$409.00K | -$90.00K | -$1.04M | -$2.26M |
| EPS Diluted | -$0.16 | -$0.04 | -$0.57 | -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR